Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00448357 · FLOW

Participant flow

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen · Source last updated 2017-07-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Experimental: GVHD prophylaxis Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine . Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus.
    id
    FG000
    title
    Experimental: GVHD Prophylaxis
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        54
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        54
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 55 subjects were consented, but one subject was not enrolled due to disease progression or death prior to protocol therapy.
recruitment Details
Patients with advanced, refractory, or high-risk hematologic cancers who were deemed suitable for myeloablative conditioning were recruited from one institution.
Complete source fields
groups
  1. description
    Experimental: GVHD prophylaxis Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine . Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus.
    id
    FG000
    title
    Experimental: GVHD Prophylaxis
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        54
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        54
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 55 subjects were consented, but one subject was not enrolled due to disease progression or death prior to protocol therapy.
recruitment Details
Patients with advanced, refractory, or high-risk hematologic cancers who were deemed suitable for myeloablative conditioning were recruited from one institution.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice